Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2015

View Archived Issues

Researchers describe novel RNAi-based bone anabolic strategy

SNP in ARNT2 gene linked to Asperger's syndrome

REGENXBIO licenses vector delivery technologies for mucopolysaccharidosis gene therapies

Novel assay for DNA methylation predicts outcome in AML patients

Teijin Pharma develops bifunctional M3 antagonist and beta2-agonist compounds

Pierre Fabre and CNRS patent DNMT inhibitors

Scientists describe IMP3 expression and chromosome 12p abnormalities in PMTT

Novel RORgt modulators identified for inflammatory diseases

Heptares Therapeutics describes discovery of mGlu5 receptor negative allosteric modulator

The Scripps Research Institute receives NCI grant to target Hippo-YAP pathway

Hydra Biosciences and Boehringer Ingelheim collaborate on TRP inhibitors for renal diseases

Voyager Therapeutics completes financing to fund AAV gene therapy development

Neothetics initiates phase III trials of LIPO-202 for reduction of subcutaneous abdominal fat

Ichor and Janssen to develop DNA vaccines for chronic HBV infection

Berg and collaborators aim to discover first biomarker for pancreatic cancer

AEternaZentaris plans confirmatory phase III trial of Macrilen in GHD diagnosis

Sthamin1 as a biomarker to distinguish ESS and ULMS from LM

Midatech and Dana-Farber Cancer Institute to collaborate on glioblastoma nanomedicines

Merck & Co. discloses HIV integrase inhibitors

Toray reports new analgesics

The CHDI Foundation discloses KMO inhibitors

University of Cologne presents apoptosis-inducing compounds

MolMed exercises option right on San Raffaele Hospital's CAR-CD44v6 project

Phase IIb trial of Nefecon for primary IgA nephropathy meets primary endpoint

Bayer expands copanlisib program with three new trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...